Close Menu

NEW YORK – Chinese precision oncology firm Genetron Health said Thursday that it has entered an exclusive licensing agreement with ImmuQuad Biotechnologies to develop and commercialize Seq-MRD, a diagnostic assay for the detection and monitoring of minimal residual disease in select hematologic cancers.

Under the agreement, Genetron gains exclusive, global rights to research, develop, commercialize, and manufacture MRD tests using Seq-MRD, which is an immunogenomics-based method for residual disease detection developed using ImmuQuad's proprietary platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.